Chetan Mishra is Founder of Rhizome AI, a Y Combinator W26 company that helps life science companies understand FDA regulatory expectations through AI-powered search across terabytes of regulatory databases. Rhizome serves 18 organizations and reads up to 1,000 documents per question with citations, eliminating hallucinations.

Chetan studied at the University of Virginia and started his career as a research engineer before transitioning to product engineering. He was the sole founding product engineer at EvolutionaryScale, launching their developer-scientist platform and scaling to tens of thousands of users and billions of API calls.

Chetan was employee number 16 at Instabase, helping banks with document and imaging processing and closing 7M in deals as the technical lead. He identified a gap in the life sciences market where many AI startups focus on drug discovery but few address bringing those drugs to market.

Rhizome AI was founded in 2023 and has raised 585K in seed funding over 2 rounds. The company has seen revenue grow 3x in recent months and serves biotech and medtech regulatory affairs teams.

Customers report that tasks taking weeks now take 10 minutes with Rhizome, with one VP of regulatory affairs stating they would cry if they lost access to the platform. The company addresses an 8 trillion dollar market cap that needs to understand FDA thinking.